GeNeuro SA, Plan-les-Ouates, Switzerland, a biopharmaceutical company developing new treatments for autoimmune diseases including multiple sclerosis, has successfully completed its initial public offering on 18 April 2016 on Euronext in Paris.
This transaction is the first ever IPO of a Swiss company on the regulated market of Euronext in Paris and the first IPO of the year on that market. The admission price and issue price of GeNeuro was set at €13 per share. Market capitalization on the day of listing was around €190m, and the IPO raised a total of €33 million.
Bär & Karrer acted as Swiss law deal counsel for GeNeuro. The team included Christophe Buchwalder, Audrey Durand and Natasa Markovic (Capital Markets & Corporate) as well as Susanne Schreiber and Francesco Carelli (Tax). Paul Hastings acted as French and U.S. deal counsel for GeNeuro. The Paul Hastings team was led in Paris by David Revcolevschi.